- Home
- NTIP vs ALGS Comparison
NTIP vs ALGS Comparison
Compare NTIP & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- ALGS
- Stock Information
- Founded
- NTIP 1990
- ALGS 2018
- Country
- NTIP United States
- ALGS United States
- Employees
- NTIP N/A
- ALGS N/A
- Industry
- NTIP Multi-Sector Companies
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- ALGS Health Care
- Exchange
- NTIP Nasdaq
- ALGS Nasdaq
- Market Cap
- NTIP 31.9M
- ALGS 36.0M
- IPO Year
- NTIP 1998
- ALGS 2020
- Fundamental
- Price
- NTIP $1.25
- ALGS $5.29
- Analyst Decision
- NTIP
- ALGS Strong Buy
- Analyst Count
- NTIP 0
- ALGS 1
- Target Price
- NTIP N/A
- ALGS $70.00
- AVG Volume (30 Days)
- NTIP 6.5K
- ALGS 163.7K
- Earning Date
- NTIP 05-09-2025
- ALGS 05-06-2025
- Dividend Yield
- NTIP 8.00%
- ALGS N/A
- EPS Growth
- NTIP N/A
- ALGS N/A
- EPS
- NTIP N/A
- ALGS N/A
- Revenue
- NTIP $250,000.00
- ALGS $3,270,000.00
- Revenue This Year
- NTIP N/A
- ALGS N/A
- Revenue Next Year
- NTIP N/A
- ALGS N/A
- P/E Ratio
- NTIP N/A
- ALGS N/A
- Revenue Growth
- NTIP N/A
- ALGS N/A
- 52 Week Low
- NTIP $1.17
- ALGS $3.76
- 52 Week High
- NTIP $1.86
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- NTIP 49.78
- ALGS 43.20
- Support Level
- NTIP $1.22
- ALGS $5.47
- Resistance Level
- NTIP $1.30
- ALGS $6.12
- Average True Range (ATR)
- NTIP 0.04
- ALGS 0.60
- MACD
- NTIP 0.00
- ALGS 0.12
- Stochastic Oscillator
- NTIP 50.00
- ALGS 37.30
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.